In Brief

Refine Search

BRIEF—Centauri given $1.25m to advance antimicrobials

UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024

BRIEF—Halozyme withdraws non-binding offer for Evotec

Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024

argenX spinoff secures series A extension to fight blood cancer

Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024

BRIEF—Brookfield mulls $7.4 billion bid for Grifols

19 November 2024

BRIEF—Eisai updates Leqembi outlook

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024

BRIEF—Boehringer drops development of Gubra’s NPY2R in obesity

Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024

BRIEF—Eisai completes rolling submission to US FDA for Leqembi maintenance dosing

Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024

$800 million investment planned at GSK Pennsylvania site

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024

BRIEF—EMA re-affirms non-renewal of masitinib and Translarna authorizations

Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024

BRIEF—UMCG and SHINE receive $11 million grant for cancer study

University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024

BRIEF—Germany becomes first country to launch LEO Pharma’s Anzupgo

Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024

BRIEF—Sanofi in talks to sell 50% of Opella

French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024

BRIEF—ABPI reviews first six months of the 2024 Voluntary Scheme

The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024

BRIEF—Sirnaomics secures $7.5 million in share subscription

Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024

GigaGen wins $135 million BARDA contract for botulinum toxin treatment

GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024

BRIEF— Enara Bio raises $32.5 million to advance pipeline

Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024

BRIEF—Mitem Pharma acquires Desferal from Novartis

French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024

article

BRIEF—Bruno Sepodes elected as EMA’s new CHMP chair

The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024

BRIEF—OeAW and Boeh-Ing Foundation establish new Institute for biomedical AI in Vienna

The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024

BRIEF—Zenas BioPharma prices upsized IPO

Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024

12 3 4 5 6 7 8 9 10 Next page

Investors unimpressed by Almirall's modest sales guidance raise

Spanish drugmaker Almirall left investors less than impressed with its latest financial results. 9 November 2023

Merck KGaA posts strong organic performance of healthcare

German pharma, science and technology company Merck KGaA today confirmed its forecast for fiscal 2023 despite a difficult market environment in the third quarter. 9 November 2023

AstraZeneca in-licenses novel agent for cardiometabolics and obesity

China-headquartered Eccogene has entered into an exclusive license agreement with AstraZeneca under which the UK pharma major will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities. 9 November 2023

Strong AstraZeneca picks obesity market for further growth

Britain’s biggest drugmaker AstraZeneca has exceeded revenues expectations handily in the third quarter 2023, with robust demand in oncology leading the way. 9 November 2023

Lilly's obesity drug gets US and UK approval, all in one day

The US Food and Drug Administration late yesterday approved US pharma major Eli Lilly’s Zepbound (tirzepatide) injection for chronic weight management in adults with obesity. 9 November 2023

New targeted therapy for bowel cancer receives approval in the USA

Japanese drug major Takeda has received US approval for Fruzaqla (fruquintinib), an oral targeted therapy for bowel cancer. 9 November 2023

Bayer continues legal disputes in Russia

German pharmaceutical major Bayer has refused compensation of more than 400 million roubles ($4.3 million) from Russian Nativa (renamed Spectrum) for the use of patents on the anticancer drug Nexavar (sorafenib), reports The Pharma Letter’s local correspondent. 9 November 2023

CMS' strategy is missing the mark: how a focus on prevention can improve health outcomes and contain costs

An Expert View from Cynthia Miller, vice president, medical director of the access experience team, PRECISIONvalue. 8 November 2023

Biogen reports better than expected 3rd-qtr 2023 results

US biotech major Biogen today reported third quarter 2023 results and updated full year 2023 guidance that failed to impress investors, with its shares falling 4.7% to $235.34 in early trading’ 8 November 2023

Gilead beats estimates with strong virology and oncology sales

Californian drugmaker Gilead Sciences has exceeded estimates in the third quarter, with revenues of around $7.1 billion and earnings per share (EPS) of $1.73. 8 November 2023

Gedeon Richter to vye for stake in Russian hypoglycemic market

Hungarian drugmaker Gedeon Richter has begun supplying generics of foreign drugs for diabetics to Russia – in a move to take the share of those global drugmakers that have left Russia, reports The Pharma Letter’s local correspondent. 8 November 2023

Teva ups revenue outlook with production unaffected by war

Israeli generics giant Teva Pharmaceutical Industries has reported its latest quarterly financial results against a backdrop of war in its home region. 8 November 2023

FTC challenges over 100 patents as improperly listed in the FDA's Orange Book

The US Federal Trade Commission (FTC) has challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products as improperly or inaccurately listed in the Food and Drug Administration’s (FDA) publication of “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.” 8 November 2023

New boss but Bayer's battles go on

German life sciences major Bayer has confirmed its group outlook for 2023 after posting third-quarter figures that were down against the previous year. 8 November 2023

Sharp earnings and sales growth reported by Lundbeck

Danish CNS specialist Lundbeck today released financials, showing that revenue increased by 10% (+9% constant exchange; CER) to 14,934 million kroner ($2,148.8 million) in the first nine months of 2023. 8 November 2023

Flagship sets sail for Asia with sights set on global expansion

East Coast, USA-based biotech incubator Flagship Pioneering is expanding into the Asia-Pacific, with a new regional hub in Singapore. 8 November 2023

Menarini sub-licenses Orserdu in China

Privately-held Italian drugmaker Menarini and USA/China-based SciClone Pharmaceuticals have entered into an exclusive sub-licensing agreement to develop and commercialize Orserdu (elacestrant) in China. 8 November 2023

Another set of strong financials from Recordati

Italian pharma major Recordati saw its shares rise 3.6% to 45.57 euros yesterday, after it released a strong set of financial results for the first-nine months of 2023. 8 November 2023

Compliance services firm makes Inflation Reduction Act update

Life science compliance specialist Model N has announced product enhancements relating to the Inflation Reduction Act. 8 November 2023

Darzalex leads Genmab to strong third quarter

Danish drugmaker Genmab has reported third quarter 2023 revenues of 4.7 billion Danish kroner ($420 million), better than the 4.5 billion kroner expected according to the FT consensus forecast. 8 November 2023

Previous page 182 183 184 185186187 188 189 190 191 Next page

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze